NCT07758270Recruiting
Brain Imaging and Immune Changes During Remibrutinib Treatment in Multiple Sclerosis.
REMIBRUTINIB: EVALUATION OF FLUID AND INFLAMMATORY NEUROIMAGING ENDPOINTS IN MULTIPLE SCLEROSIS (REDEFINE-MS)
Source: ClinicalTrials.gov · Last updated 11 Aug 2026
Brief summary (registry, in English)
REDEFINE-MS is a research study for people with relapsing multiple sclerosis (MS) who are participating in the RESHAPE-MS trial. The study aims to better understand how remibrutinib affects inflammation in the brain and spinal cord by using PET imaging, MRI scans, blood samples, and cerebrospinal fluid (CSF) samples collected before treatment and again six months later. \[REDEFINE\_p...2026\_clean \| Word\] The main question the study is trying to answer is whether remibrutinib changes immune activity and inflammation in people with MS, and whether these changes can be measured using imaging and biological markers that may help predict future disease progression and treatment response.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 15 (estimated)
- First submitted
- 5 Aug 2026
- Start date
- 15 Aug 2026
- Primary completion date
- 15 Aug 2029
- Lead sponsor
- Washington University School of Medicine
- Diseases
- Multiple sclerosis
- NCT number
- NCT07758270
What you commit to
- Study type: Observational
- Planned participants: 15
- From 15 Aug 2026 to the primary completion date, 15 Aug 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current or recent (within 12 months prior to screening) participation in research studies involving radioactive agents such that the total research-related radiation dose to the participant in any given year would exceed the limits set forth in the U.S. Code of Federal Regulations (CFR) Title 21 Section 361.1. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?FR=361.1.
Other illness
- Hypersensitivity to \[11C\]-DPA-713 or any of its excipients
- Any condition that, in the opinion of the Principal Investigator or his designee, could increase the risk to the participant or limits their ability to participate (e.g., liver or kidney disease, advanced cancer)
Other
- The exclusion criteria of the parent study are adapted and inherited under this section (See parent study protocol section 5.2). In addition, the following exclusion criteria apply:
- Contraindications to PET or MRI (e.g. certain incompatible electronic medical devices, inability to lie still for extended periods) that make it potentially unsafe for the individual to participate
- Presence of a low affinity binding TSPO polymorphism.
Who the study is looking for
- Capable of providing written informed consent for volunteering to undergo research procedures.
- Male or female, any race
- Age between 40 and 70 years of age, inclusive
- Diagnosis of RMS according to revised 2017 McDonald criteria at screening 15
- EDSS score of 0 to 6.5 (inclusive) at screening
- Treated with ocrelizumab according to routine clinical practice and at standard dose for at least 18 months. The last administration of ocrelizumab must have occurred within 5 to 9 months prior to randomization.
- Neurologically stable within 30 days prior to screening, including no MS relapse during this period.
- Suitable to be switched to remibrutinib based on physician judgement or patient preference.
Age in the registry: 40 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Washington University School of Medicine in St. Louis Coordinator of this site? Confirm its status | St Louis | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.